NCT02092597View on ClinicalTrials.gov

Safety Evaluation of Adverse Reactions in Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

October 31, 2015

Study Completion Date

September 30, 2016

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Exenatide

DRUG

Linagliptin

DRUG

Gliclazide

Trial Locations (1)

128 08

General University Hospital, Prague

All Listed Sponsors
lead

Charles University, Czech Republic

OTHER

NCT02092597 - Safety Evaluation of Adverse Reactions in Diabetes | Biotech Hunter | Biotech Hunter